GTBP beat EPS expectations by 49.45%
May 22, 2025, 10:33 PM
0.00%
What does GTBP do
GT Biopharma, a clinical-stage biopharmaceutical company based in Brisbane, California, focuses on immuno-oncology products using its TriKE NK cell engager platform, with its first candidate, GTB-3550, targeting cancer and HIV. Founded in 2013, the company employs two full-time staff and aims to enhance natural killer cell activity against diseases.
GT Biopharma (GTBP) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, GT Biopharma's actual EPS was -$0.33, beating the estimate of -$0.65 per share, resulting in a 49.45% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.